Results 151 to 160 of about 102,331 (342)

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

CHILDREN EXPOSED TO METHADONE IN-UTERO: COGNITIVE ABILITY IN THE PRESCHOOL YEARS [PDF]

, 1987
Karol Kaltenbach, Loretta P. Finnegan
openalex   +1 more source

Statistical Proof and Theories of Discrimination [PDF]

, 1986
We live in a tightly knit world. Our emotions, desires, perceptions and decisions are interlinked in our interactions with others. We are constantly influencing our surroundings and being influenced by others.
Laycock, Douglas
core   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source

Accidental ingestion of methadone by children in Merseyside [PDF]

, 1994
James Binchy, E Molyneux, Joseph C. Manning   +2 more
openalex   +1 more source

Troriluzole attenuates opioid intake, reinforcing efficacy, seeking behaviours, physical dependence and antinociceptive tolerance in rats

British Journal of Pharmacology, EarlyView.
Background and Purpose Riluzole, approved for amyotrophic lateral sclerosis (ALS), has a glutamate‐modulating profile favourable for mitigating opioid addiction. It reduces neuronal glutamate release and enhances glutamate reuptake, offering advantages over agents that only increase glutamate reuptake.
Ewa Galaj, Saadet Inan, Guo‐Hua Bi, Sonita Wiah, George Adamson, Allen B. Reitz, Zheng‐Xiong Xi, Scott M. Rawls   +7 more
wiley   +1 more source

Rx: 3x/week LAAM alternative to methadone.

, 1976
Jack Blaine, Pierre F. Renault
openalex   +2 more sources

Patterns of drug use by participants in the Western Australian methadone program, 1984‐1991 [PDF]

, 1993
Greg Swensen, Kenneth F. Ilett, Leon J. Dusci, L. Peter Hackett, Robert T. T Ong, Allan J. Quigley, Simon Lenton, Richard Saker, Jane Caporn   +8 more
openalex   +1 more source

Perceived Barriers and Potential Strategies for People Who Use Drugs in Accessing Oral Healthcare: A Qualitative Study of Service Providers

Community Dentistry and Oral Epidemiology, EarlyView.
ABSTRACT Objective Access to appropriate oral healthcare is vital for overall health and well‐being. However, people who use drugs (PWUD) often face significant barriers in accessing oral healthcare services. This qualitative study focused on exploring the perspectives of public oral health service providers and harm reduction workers to understand the
Tejashree Kangutkar, Mark Gussy, Ronald Knevel, Hanny Calache   +3 more
wiley   +1 more source

Methadone maintenance in general practice: patients, workload, and outcomes [PDF]

, 1994
Philip Wilson, Roger Watson, George Ralston   +2 more
openalex   +1 more source